search
Back to results

Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With WPW Pattern

Primary Purpose

Wolff-Parkinson-White Syndrome, Sudden Cardiac Death, Risk Stratification

Status
Unknown status
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Stress test (ECG)
Sponsored by
Christian Balmer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Wolff-Parkinson-White Syndrome

Eligibility Criteria

8 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed Consent as documented by signature (Appendix Informed Consent Form)
  • Preexcitation in resting ECG (WPW ECG Pattern)
  • Age between 8 and 18 years
  • Invasive EPS must be indicated/planned at the Children's Hospital Zurich

Exclusion Criteria:

  • Inability to follow the procedures of the study, e.g. due to language problems or psychological disorders of the participant
  • Inability to walk/run on a treadmill

Sites / Locations

  • University Childrens Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Stress ECG Test

Arm Description

The whole study cohort undergoes the same diagnostic workup including stress test (ECG)

Outcomes

Primary Outcome Measures

Cycle length (CL) at the Stress ECG Test
Cycle length (ms) at the point when the delta wave disappears and/or at the point of maximal heart rate (HR) (ms)

Secondary Outcome Measures

ERP-AP from invasive EPS
Effective Refractory Period of Accessory Pathways (ERP-AP) during programmed atrial pacing (ms)
SPERRI from invasive EPS
Shortest pre excited Interval between two cardiac cycles (SPERRI)
Anatomical localisation of the AP measured in the EPS
leftsided (superior, posterosuperior, posterior, posteroinferior, inferior) or rightsided (paraseptal, inferior, anteroinferior, anterior, anterosuperior and superior)

Full Information

First Posted
March 8, 2017
Last Updated
June 17, 2020
Sponsor
Christian Balmer
search

1. Study Identification

Unique Protocol Identification Number
NCT03207373
Brief Title
Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With WPW Pattern
Official Title
Reproducibility and Validity of the Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With Preexcitation (WPW Pattern)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Unknown status
Study Start Date
April 13, 2017 (Actual)
Primary Completion Date
February 2021 (Anticipated)
Study Completion Date
March 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Christian Balmer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with preexcitation are at risk for sudden cardiac death. The pathogenesis is a rapid antegrade conduction of atrial fibrillation over the accessory pathway to the ventricle resulting in ventricular fibrillation. Today it is possible to eliminate the conduction over the accessory pathway by catheter intervention (radiofrequency ablation) with a low rate of complications and a high rate of success. In clinical practice it is therefore important to estimate the risk for sudden cardiac death in an individual patient to give an advice to the patient and the parents about the further evaluation and therapeutic strategy. The velocity of the conduction over the accessory pathway can be estimated by analysing the ECG during sinus tachycardia. If the preexcitation disappears at a relatively low heart rate, the risk for sudden death is less than in patients with persisting preexcitation at the maximal heart rate. Compared to the gold standard i.e. measurement of the refractory period of the accessory pathway during invasive electrophysiological study (EPS), the measurements at the stress ECG have been reported to be a relatively poor indicator for an elevated risk which may be explained by a high intraindividual variability of this test. This study is designed to define the clinical relevance of the stress ECG in paediatric patients with preexcitation (compared to the invasive electrophysiological study). First Hypothesis: The results of the 3 stress ECG-tests are reproducible in an individual patient. Null hypothesis: there is no difference between the three measurements of cycle length during stress ECG. Alternate hypothesis: the difference between the three measurements of cycle length is > 10%. Second Hypothesis: There is a close correlation between the results at stress ECG and the results at the invasive electrophysiological Intervention.
Detailed Description
Single centre, interventional study. There will be no randomisation or blinding. This study evaluates the stress ECG test as a non-invasive method of risk stratification in patients with WPW syndrome. For the non-invasive part a stress electrocardiogram on a treadmill is used. The invasive comparison is made with an electrophysiological study (EPS) in the catheterization laboratory. Nowadays the gold standard for measuring the antegrade effective refractory period of the accessory pathway is the invasive EPS. Study category A; there is only a minimal risk and a minimal burden to the study participants; The stress ECG test is a recommended test for this specific patient group as indicated in international guidelines. The responsible investigator at the single study site ensures that approval from an appropriately constituted Competent Ethics Committee (CEC), is sought for the clinical study. Objectives: 1) The study seeks primarily to evaluate the reproducibility of the loss of the preexcitation in repetitive stress ECG test in paediatric patients with WPW pattern in the view of an accurate estimation of the individual risk for sudden cardiac death. 2) To compare the results of non-invasive ECG measurements with measurements taken during invasive EPS and clinical/anatomical parameters. Planned Analysis: Descriptive statistic is applied to all clinical parameters. All the 3 cycle lengths out of the stress ECG are compared individually with the ERP-AP from the invasive EPS. If there is an average from the cycle length, this would be compared with the ERP-AP as well. And then we compare whether the difference between the cycle length and the ERP-AP is similar in a group of patients (high/low risk) or even in all patients. To demonstrate those results we use the Bland-Altman plot. There will also be a graph with the distribution of age of all patients. It will be interesting to see whether the age influences the results for example in relation to high or low risk. After the EPS, the patients are divided into 2 risk categories: high risk (ERP-AP ≤ 250 ms) and low risk (ERP-AP > 250ms) as measured at the EPS. At the end a risk factor analysis is made. All the parameters out of the case report form will be analysed whether the patient has high or low risk.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wolff-Parkinson-White Syndrome, Sudden Cardiac Death, Risk Stratification

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Stress ECG Test
Arm Type
Experimental
Arm Description
The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
Intervention Type
Diagnostic Test
Intervention Name(s)
Stress test (ECG)
Intervention Description
Every study participant undergoes a standard diagnostic stress ECG
Primary Outcome Measure Information:
Title
Cycle length (CL) at the Stress ECG Test
Description
Cycle length (ms) at the point when the delta wave disappears and/or at the point of maximal heart rate (HR) (ms)
Time Frame
3 test within a month
Secondary Outcome Measure Information:
Title
ERP-AP from invasive EPS
Description
Effective Refractory Period of Accessory Pathways (ERP-AP) during programmed atrial pacing (ms)
Time Frame
1 single measurement at aprox 1 month
Title
SPERRI from invasive EPS
Description
Shortest pre excited Interval between two cardiac cycles (SPERRI)
Time Frame
1 single measurement at aprox 1 month
Title
Anatomical localisation of the AP measured in the EPS
Description
leftsided (superior, posterosuperior, posterior, posteroinferior, inferior) or rightsided (paraseptal, inferior, anteroinferior, anterior, anterosuperior and superior)
Time Frame
1 single measurement at aprox 1 month
Other Pre-specified Outcome Measures:
Title
Heart rate of 12-lead Resting ECG
Description
(bpm)
Time Frame
1 single measurement within 1 month
Title
Rhythm during 12-lead Resting ECG
Description
sinus rhythm yes/no
Time Frame
1 single measurement within 1 month
Title
axis of the QRS complex out of the 12-lead Resting ECG
Description
(degree)
Time Frame
1 single measurement within 1 month
Title
Duration of PQ Interval out of the 12-lead Resting ECG
Description
(ms)
Time Frame
1 single measurement within 1 month
Title
Duration of the QRS complex (ms) out of the 12-lead Resting ECG
Description
(ms)
Time Frame
1 single measurement within 1 month
Title
Z-value of left ventricle (LV) out of Echocardiography
Description
Z-value LV
Time Frame
1 single measurement at aprox 1 month
Title
Z-value of right ventricle (RV) out of Echocardiography
Description
Z-value RV
Time Frame
1 single measurement within 1 month
Title
Z-value of left Atrium (LA) out of Echocardiography
Description
Z-value LA
Time Frame
1 single measurement within 1 month
Title
Shortening fraction (SF) measured in Echocardiography
Description
SF (%)
Time Frame
1 single measurement within 1 month
Title
Ejection fraction (EF) measured in Echocardiography 5
Description
EF (%)
Time Frame
1 single measurement within 1 month
Title
Valvular insufficiency measured in Echocardiography
Description
aorta-, pulmonal-, tricuspidal-, mitral insufficiency (no, minimal, moderate, severe)
Time Frame
1 single measurement within 1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed Consent as documented by signature (Appendix Informed Consent Form) Preexcitation in resting ECG (WPW ECG Pattern) Age between 8 and 18 years Invasive EPS must be indicated/planned at the Children's Hospital Zurich Exclusion Criteria: Inability to follow the procedures of the study, e.g. due to language problems or psychological disorders of the participant Inability to walk/run on a treadmill
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christian Balmer, PD Dr. med.
Organizational Affiliation
University Childrens Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Childrens Hospital
City
Zurich
ZIP/Postal Code
8090
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With WPW Pattern

We'll reach out to this number within 24 hrs